NO994303L - Krystallinsk hydrert natriumsalt av (E)-4,6-diklor-3-(2-okso-1-fenylpyrrolidin-3-ylidenmetyl)-1H-indol-2-karboksylsyre - Google Patents

Krystallinsk hydrert natriumsalt av (E)-4,6-diklor-3-(2-okso-1-fenylpyrrolidin-3-ylidenmetyl)-1H-indol-2-karboksylsyre

Info

Publication number
NO994303L
NO994303L NO994303A NO994303A NO994303L NO 994303 L NO994303 L NO 994303L NO 994303 A NO994303 A NO 994303A NO 994303 A NO994303 A NO 994303A NO 994303 L NO994303 L NO 994303L
Authority
NO
Norway
Prior art keywords
sodium salt
ylidenomethyl
phenylpyrrolidin
indole
dichloro
Prior art date
Application number
NO994303A
Other languages
English (en)
Norwegian (no)
Other versions
NO994303D0 (no
Inventor
Zadeo Cimarosti
Paolo Maragni
Original Assignee
Glaxo Wellcome Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Spa filed Critical Glaxo Wellcome Spa
Publication of NO994303D0 publication Critical patent/NO994303D0/no
Publication of NO994303L publication Critical patent/NO994303L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO994303A 1997-03-05 1999-09-03 Krystallinsk hydrert natriumsalt av (E)-4,6-diklor-3-(2-okso-1-fenylpyrrolidin-3-ylidenmetyl)-1H-indol-2-karboksylsyre NO994303L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9704498.6A GB9704498D0 (en) 1997-03-05 1997-03-05 Chemical compound
PCT/EP1998/001146 WO1998039327A1 (en) 1997-03-05 1998-03-03 Crystalline hydrated sodium salt of (e)-4,6-dichloro-3-(2-oxo-1-phenylpyrrolidin-3-ylidene methyl)-1h-indole-2-carboxylic acid

Publications (2)

Publication Number Publication Date
NO994303D0 NO994303D0 (no) 1999-09-03
NO994303L true NO994303L (no) 1999-11-03

Family

ID=10808697

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994303A NO994303L (no) 1997-03-05 1999-09-03 Krystallinsk hydrert natriumsalt av (E)-4,6-diklor-3-(2-okso-1-fenylpyrrolidin-3-ylidenmetyl)-1H-indol-2-karboksylsyre

Country Status (29)

Country Link
EP (1) EP0966463A1 (is)
JP (1) JP2001513796A (is)
KR (1) KR20000075907A (is)
CN (1) CN1249750A (is)
AP (1) AP9901637A0 (is)
AR (1) AR011178A1 (is)
AU (1) AU6825198A (is)
BG (1) BG103779A (is)
BR (1) BR9808305A (is)
CA (1) CA2282851A1 (is)
CO (1) CO4940415A1 (is)
EA (1) EA199900710A1 (is)
EE (1) EE9900387A (is)
GB (1) GB9704498D0 (is)
HR (1) HRP980114A2 (is)
HU (1) HUP0002109A2 (is)
ID (1) ID24207A (is)
IL (1) IL131489A0 (is)
IS (1) IS5166A (is)
NO (1) NO994303L (is)
NZ (1) NZ337315A (is)
OA (1) OA11154A (is)
PE (1) PE51399A1 (is)
PL (1) PL335652A1 (is)
SK (1) SK119699A3 (is)
TR (1) TR199902117T2 (is)
WO (1) WO1998039327A1 (is)
YU (1) YU43499A (is)
ZA (1) ZA981791B (is)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9704499D0 (en) * 1997-03-05 1997-04-23 Glaxo Wellcome Spa Method of manufacture
GB9825988D0 (en) * 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
CN110996948A (zh) 2017-06-12 2020-04-10 格莱泰施有限责任公司 用nmda拮抗剂和d2/5ht2a或选择性5ht2a拮抗剂治疗抑郁症

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321221D0 (en) * 1993-10-14 1993-12-01 Glaxo Spa Heterocyclic compounds

Also Published As

Publication number Publication date
GB9704498D0 (en) 1997-04-23
WO1998039327A1 (en) 1998-09-11
BR9808305A (pt) 2000-05-16
EP0966463A1 (en) 1999-12-29
ID24207A (id) 2000-07-13
EE9900387A (et) 2000-04-17
CO4940415A1 (es) 2000-07-24
PE51399A1 (es) 1999-06-07
IS5166A (is) 1999-08-27
IL131489A0 (en) 2001-01-28
AU6825198A (en) 1998-09-22
SK119699A3 (en) 2000-05-16
KR20000075907A (ko) 2000-12-26
ZA981791B (en) 1999-09-03
TR199902117T2 (xx) 2000-03-21
HRP980114A2 (en) 1998-12-31
PL335652A1 (en) 2000-05-08
JP2001513796A (ja) 2001-09-04
OA11154A (en) 2003-04-16
CN1249750A (zh) 2000-04-05
NO994303D0 (no) 1999-09-03
AP9901637A0 (en) 1999-09-30
YU43499A (sh) 2000-12-28
NZ337315A (en) 2001-02-23
EA199900710A1 (ru) 2000-04-24
AR011178A1 (es) 2000-08-02
BG103779A (en) 2000-06-30
CA2282851A1 (en) 1998-09-11
HUP0002109A2 (hu) 2001-04-28

Similar Documents

Publication Publication Date Title
CA2260337A1 (en) Therapeutic agents
TW200407287A (en) A sulfonated amine acid derivative and the metalloproteinase inhibitor containing it (I)
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
TR199700844T1 (xx) Pirazolil-Benzoil T�revleri.
DK0977741T3 (da) Substituerede phenylderivater, deres fremstilling og anvendelse
MXPA02003977A (es) Inhibidores de adhesion de celula mediada por al°2.
NO20022558L (no) 4-karboksyamino-2-etyl-1,2,3,4-tetrahydrokinolinkrystall som CETP inhibitor
IL135921A0 (en) Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
NO996108L (no) 9-oksinerytromycinderivater
DE69924292D1 (de) Pyrazol verbindungen und ihre verwendung
TR200002605T2 (tr) Nitrik oksit sentaz inhibitörleri olarak faydalı halojene amidino amino asit türevleri
TR199700206A2 (xx) Floralkil- ve floralkoksi ikame edilmi� heterosiklik bradikinin-antagonistleri, bunlar�n imal edilmesine mahsus usul ve bunlar�n kullan�lmalar�.
NO964348L (no) CCK- eller gastrin-modulerende 5-hetrocykliske-1,5-benzodiazepiner
TR200001909T2 (tr) Matris metaloprotez inhibitörleri.
AP9901637A0 (en) Crystalline hydrated sodium salt of (E)-4,6-dichloro-3-(2-oxo-1-phenylpyrrolidin-3-ylidene methyl)-1H-indole-2-carboxylic acid.
IL142776A0 (en) Use of phosphonoformic acid derivatives for treating infections
AU4944899A (en) New pharmaceutically active compounds
JO2240B1 (en) Method for preparing dithylidene derivatives
PT1104419E (pt) Derivados de azabicicloheptano substituidos no azoto sua preparacao e utilizacao
ATE286892T1 (de) Hydroxam- und carbonsäurederivate mit mmp- und tnf-hemmender aktivität
PL348354A1 (en) Use of phosphonoformic acid derivatives for treating infections
EE200200227A (et) Tüüp 1 naatrium-vesinik ioniidi inhibiitori kristallid
ZA9810361B (en) Heterocyclic compounds having MMP and TNF inhibitory activity.
HK1022899A (en) Crystalline hydrated sodium salt of (e)-4, 6-dichloro-3-(2-oxo-1-phenylpyrrolidin-3-ylidene methyl)-1h-indole-2-carboxylic acid
ATE56445T1 (de) Pharmacologisch aktive propionylanilide.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application